Cytokine clearance in AKI (ClicAKI)

  • Research type

    Research Study

  • Full title

    Clearance of inflammatory cytokines in patients with septic acute kidney injury during renal replacement therapy using the EMIC®2 filter (ClicAKI)

  • IRAS ID

    196972

  • Contact name

    Marlies Ostermann

  • Contact email

    Marlies.Ostermann@gstt.nhs.uk

  • Sponsor organisation

    Guy's & St Thomas' Hospital

  • Clinicaltrials.gov Identifier

    NCT03231748

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Sepsis is the inflammatory response to an infection. It can cause poor function of all organs and can be life threatening. Critically ill patients with sepsis and acute kidney failure have a particularly high risk of dying. A proportion of patients with acute kidney failure need dialysis treatment to remove excess fluid and toxins. \n\nThe EMiC®2 filter is a new dialysis filter with slightly larger pores than conventional filters. As a result, larger molecules can be removed during dialysis. The filter is fully approved for use and has been shown to be safe in previous small studies. It is routinely used in some hospitals in Europe.\n\nThe aim of our pilot study is to investigate whether the EMiC®2 filter can remove cytokines which are inflammatory molecules produced in sepsis. We plan to measure different pro- and anti-inflammatory cytokines at different time points in 10 patients with sepsis who are treated with acute dialysis. \n\nWith consent, we plan to take a blood sample before acute dialysis is started. Whilst on acute dialysis we plan to take further blood and dialysate samples at different time points up to 52 hours.In total we will take no more than 27mls of blood and up to 30mls of dialysate. The amount of blood taken will not cause any harm to the patient; dialysate fluid is usually discarded. \nThere will be no change in treatment or clinical management. \n\nThe results of this pilot project will help us to decide whether further studies are necessary to investigate the benefit and risks of removing cytokines in patients with sepsis and acute kidney failure.

  • REC name

    London - Camden & Kings Cross Research Ethics Committee

  • REC reference

    16/LO/0313

  • Date of REC Opinion

    27 May 2016

  • REC opinion

    Further Information Favourable Opinion